Drug Trial News

RSS

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body.

11 Oct 2022

Oxford researchers report findings from Phase 1 clinical trial of intranasal COVID-19 vaccine

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the safety and immune response of an intranasally-administered vaccine against COVID-19.

11 Oct 2022

Clinical trials of novel COVID-19 vaccine developed in Brazil to begin soon

Testing on humans of a novel COVID-19 vaccine developed in Brazil will begin this year. It performed well in animal trials, as reported in an article published in August in Nature Communications.

6 Oct 2022

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs.

4 Oct 2022

Eligibility criteria lack clarity, justification for excluding people with disabilities from clinical trials

Despite constituting the largest minority group in the U.S. and expressing interest in participating in clinical trials, people with disabilities remain excluded.

3 Oct 2022

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

29 Sep 2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate).

27 Sep 2022

First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine

In a recent study posted to the bioRxiv* preprint server, researchers from Germany and the United States analyzed the association between exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/BA.5 spike glycoprotein and pan-Omicron neutralization.

27 Sep 2022

Study looks at boosting with variant-derived COVID vaccine

In a recent study posted to bioRxiv*, researchers at Washington University School of Medicine, St. Louis, demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster elicits robust germinal center (GC) B cell responses.

26 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

In a recent study posted to the medRxiv* preprint server, researchers in the United States described the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tested in PREVENT-19 — a phase 3, randomized, placebo-controlled, observer-blinded trial among 12- to 17-year-old adolescents in the United States (U.S).

25 Sep 2022

Anti-fibrotics found to be safe, effective for interstitial lung disease in patients with rheumatoid arthritis

For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

22 Sep 2022

Large clinical trial compares four drugs commonly used to treat type 2 diabetes

In a large clinical trial that directly compared four drugs commonly used to treat type 2 diabetes, researchers found that insulin glargine and liraglutide performed the best of four medications approved by the U.S. Food and Drug Administration to maintain blood glucose levels in the recommended range.

21 Sep 2022

An improved COVID-19 vaccine shows promise against Omicron in experimental models

In a recent study published in the journal Science Translational Medicine, researchers in the United States designed a bivalent coronavirus disease 2019 (COVID-19) vaccine on the messenger ribonucleic acid (mRNA) platform.

18 Sep 2022

UCLA announces participation in a phase 3 trial evaluating tecovirimat for the treatment of monkeypox

The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.

16 Sep 2022

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus.

16 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.

13 Sep 2022

$Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer$

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

13 Sep 2022

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

13 Sep 2022

Previous
1
...
28
29
30
31
32
33
34
...
1143
Next

Drug Trial News

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Oxford researchers report findings from Phase 1 clinical trial of intranasal COVID-19 vaccine

Clinical trials of novel COVID-19 vaccine developed in Brazil to begin soon

Early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis begins

Eligibility criteria lack clarity, justification for excluding people with disabilities from clinical trials

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine

Study looks at boosting with variant-derived COVID vaccine

Designing a new treatment to treat migraine effectively

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

Anti-fibrotics found to be safe, effective for interstitial lung disease in patients with rheumatoid arthritis

Large clinical trial compares four drugs commonly used to treat type 2 diabetes

An improved COVID-19 vaccine shows promise against Omicron in experimental models

UCLA announces participation in a phase 3 trial evaluating tecovirimat for the treatment of monkeypox

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News